Existing investor Boehringer Ingelheim Venture Fund co-led the cell therapy developer's series A round, which also featured MBL Venture Capital.
Boehringer Ingelheim Venture Fund, the strategic investment arm of pharmaceutical company Boehringer Ingelheim, has co-led a $12m series A round for US-based cell therapy developer Sentien Biotechnologies.
The round was co-led by life sciences investment platform BioInnovation Capital and included MBL Venture Capital, the corporate venturing subsidiary of Medical & Biological Laboratories, as well as Chiesi Ventures and Mass Medical Angels.
Sentien is working on an acute kidney injury treatment known as SBI-101 that will combine mesenchymal stromal cells (MSCs)…
